항혈전약 시장 규모, 점유율, 성장 분석 : 유형별, 약제 클래스별, 적응증별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Antithrombotic Drugs Market Size, Share, and Growth Analysis, By Type (Apixaban, Debigatran), By Drug Class, By Indication, By Route of Administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1789232
리서치사:SkyQuest
발행일:2025년 08월
페이지 정보:영문 176 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 항혈전약 시장 규모는 2023년에 484억 달러로 평가되며, 2024년 522억 2,000만 달러에서 2032년에는 959억 5,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 7.9%로 성장할 전망입니다.
항혈전제 세계 시장은 특히 심혈관 질환의 유병률 증가, 노인 인구 증가, 신규 경구용 항응고제(NOACs)에 대한 수요 증가 등 여러 가지 강력한 요인에 의해 주도되고 있습니다. 심방세동, 정맥혈전색전증과 같은 심혈관 질환은 전 세계 보건 문제이며, 이러한 약물에 대한 큰 수요를 견인하고 있습니다. 또한 고령층은 점점 더 혈전성 질환에 걸리기 쉬워지고 있으며, 환자층은 더욱 확대되고 있습니다. 다비가트란, 리바록사반과 같은 NOAC은 편리성과 낮은 상호작용 및 출혈 위험으로 인해 많은 사랑을 받고 있습니다. 또한 예방적 건강관리에 대한 인식이 높아짐에 따라 더 큰 보급을 촉진하고 있습니다. 그러나 출혈 위험, 높은 약값, 엄격한 규제 등의 문제는 시장 성장을 저해할 수 있는 요인으로 작용할 수 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
사례 연구
고객 구매 행동 분석
항혈전약 시장 규모 : 유형별 & CAGR(2025-2032)
시장 개요
Apixaban
Debigatran
Edoxaban
Fondaparinux
Heparin
Rivaroxaban
항혈전약 시장 규모 : 약제 클래스별 & CAGR(2025-2032)
시장 개요
혈전용해약
항혈소판제
항응고제
기타
항혈전약 시장 규모 : 적응증별 & CAGR(2025-2032)
시장 개요
심방세동
뇌졸중
심부정맥혈전증(DVT)
폐색전증(PE)
기타
항혈전약 시장 규모 : 투여 경로별 & CAGR(2025-2032)
시장 개요
경구
주사
기타
항혈전약 시장 규모 : 최종사용자별 & CAGR(2025-2032)
시장 개요
병원
전문 클리닉
홈케어
기타
항혈전약 시장 규모 : 유통 채널별 & CAGR(2025-2032)
시장 개요
병원 약국
소매 약국
온라인 약국
기타
항혈전약 시장 규모 : 지역별 & CAGR(2025-2032)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
최근 시장 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
기업의 상세
제품 포트폴리오 분석
기업의 부문별 점유율 분석
매출의 전년대비 비교(2022-2024년)
주요 기업 개요
F. Hoffmann-La Roche Ltd.(Switzerland)
Teva Pharmaceutical Industries Ltd.(Ireland)
Sanofi(France)
Pfizer Inc.(U.S.)
GlaxoSmithKline plc(U.K.)
Novartis AG(Switzerland)
Merck & Co., Inc.(U.S.)
Allergan(Ireland)
AstraZeneca(U.K.)
Johnson & Johnson Private Limited(U.S.)
Hikma Pharmaceuticals PLC(U.K.)
Fresenius Kabi AG(Germany)
Eisai Co., Ltd.(Japan)
Bristol-Myers Squibb Company(U.S.)
Bayer AG(Germany)
DAIICHI SANKYO COMPANY, LIMITED(Japan)
결론과 제안
KSA
영문 목차
영문목차
Global Antithrombotic Drugs Market size was valued at USD 48.4 billion in 2023 and is poised to grow from USD 52.22 billion in 2024 to USD 95.95 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).
The global market for antithrombotic drugs is being propelled by several influential factors, particularly the growing prevalence of cardiovascular diseases, an expanding geriatric population, and a heightened demand for novel oral anticoagulants (NOACs). Cardiovascular issues, including atrial fibrillation and venous thromboembolism, represent a leading global health challenge, driving significant demand for these medications. Moreover, the elderly demographic is increasingly susceptible to thrombotic disorders, further widening the patient pool. NOACs, such as dabigatran and rivaroxaban, are gaining traction for their convenience and lower risk of interactions and bleeding. Additionally, rising awareness regarding preventive healthcare is fostering greater adoption. However, challenges such as the risk of bleeding, the high cost of medications, and stringent regulatory hurdles could hinder market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antithrombotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Antithrombotic Drugs Market Segments Analysis
Global Antithrombotic Drugs Market is segmented by Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin and Rivaroxaban. Based on Drug Class, the market is segmented into Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants and Others. Based on Indication, the market is segmented into Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE) and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Antithrombotic Drugs Market
The increasing incidence of cardiovascular conditions such as atrial fibrillation, deep vein thrombosis, and strokes has significantly boosted the demand for antithrombotic medications. Contributing factors include a rising population, sedentary lifestyles, and the prevalence of metabolic syndrome, all of which underscore the importance of anticoagulants and antiplatelet agents. These medications are essential not only for immediate treatment but also for the long-term management of cardiovascular risks. As awareness of these health issues grows and preventive measures become more vital, the antithrombotic drugs market is expected to expand further, catering to the urgent need for effective therapeutic solutions.
Restraints in the Global Antithrombotic Drugs Market
The Global Antithrombotic Drugs market faces significant limitations due to the increased risk of bleeding associated with these medications, particularly in elderly individuals or those with additional health conditions. This elevated risk complicates clinical decision-making and often necessitates continuous monitoring, adjustments in dosage, or even the cessation of treatment. Such safety concerns can diminish physicians' confidence and affect patient adherence, ultimately impacting overall market penetration and the long-term success of therapy. As a result, healthcare providers must carefully weigh the benefits and drawbacks, which may hinder the widespread adoption of antithrombotic treatments in various patient populations.
Market Trends of the Global Antithrombotic Drugs Market
The global antithrombotic drugs market is witnessing a notable trend towards next-generation targeted therapies that prioritize ultra-specificity in targeting coagulation factors. This innovative approach aims to minimize bleeding risks while maintaining sustained efficacy, catering to the urgent demand for safer treatment options. By precisely addressing pathological processes, these advanced therapies promise to enhance safety profiles compared to existing medications, facilitating personalized treatment strategies that effectively balance clot prevention with bleeding control. As healthcare professionals increasingly seek tailored solutions for patients, the adoption of these cutting-edge antithrombotic therapies is expected to drive market growth and transformation in patient care.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer Buying Behavior Analysis
Global Antithrombotic Drugs Market Size by Type & CAGR (2025-2032)
Market Overview
Apixaban
Debigatran
Edoxaban
Fondaparinux
Heparin
Rivaroxaban
Global Antithrombotic Drugs Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Thrombolytic Drugs
Anti-Platelet Drugs
Anticoagulants
Others
Global Antithrombotic Drugs Market Size by Indication & CAGR (2025-2032)
Market Overview
Atrial Fibrillation
Stroke
Deep vein thrombosis (DVT)
Pulmonary Embolism (PE)
Others
Global Antithrombotic Drugs Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Injectable
Others
Global Antithrombotic Drugs Market Size by End User & CAGR (2025-2032)
Market Overview
Hospitals
Specialty Clinics
Homecare
Others
Global Antithrombotic Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Global Antithrombotic Drugs Market Size & CAGR (2025-2032)
North America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
US
Canada
Europe (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
